DW Insights & Inquiries
Few would question biologics’ remarkable efficacy, yet many seem surprised by their paradoxical reactions. Years ago, when psoriatic flares with TNF inhibitors were initially reported, clinicians were justifiably perplexed.
As a medical dermatologist, I have never used hyaluronidase, but recent reports suggest that I might. HA has important biological and physiological functions that have been under-appreciated until recently.
Dupilumab has been a valuable addition to dermatologists’ therapeutic palette in managing atopic dermatitis. The biologic agent was released in 2017 and is now approved for patients who are at least 12 years old.
Reflections on how far dermatology has come over the last decade. These advances will accelerate over the next decade — I anticipate that the holiday commentary for 2030 will be breathtaking!
Trifarotene, a novel first‐in‐class fourth‐generation topical retinoid, is a selective RAR γ agonist. In multiple mouse models trifarotene exhibited superior comedolytic, anti‐inflammatory, and depigmenting activity.
There is considerable inconsistency in how pathologists diagnose melanocytic neoplasms. New research described here finds less than 50% concordance among pathologists in properly classifying lesions across lesion types.
The goal of this website is to improve the practice of dermatology, while being stimulating, practical, thought-provoking, and enlightening. Perspectives on current dermatologic literature are offered that are meant to be used in the clinic.
Explore Dermatology World Insights and Inquiries clinical topics by practice focus, condition, and medical journal source.